Ulipristal acetate
| Code | Size | Price |
|---|
| CDX-U0027-M050 | 50 mg | £164.00 |
Quantity:
| CDX-U0027-M100 | 100 mg | £267.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
(11beta)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; CDB-2914; HRP 2000; RU 44675
Appearance:
White to light yellow crystalline powder.
CAS:
126784-99-4
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H361fd
InChi:
InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1
InChiKey:
OOLLAFOLCSJHRE-ZHAKMVSLSA-N
Long Description:
Chemical. CAS: 126784-99-4. Formula: C30H37NO4. MW: 475.62. Synthetic. Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC50s=8.5 and 7.7nM, respectively), rabbit uterine PR (EC50=13.6nM), and rabbit thymic glucocorticoid receptor (GR; EC50=15.4nM). It is selective for human progesterone receptors over the human estrogen receptor (ER; EC50>10,000nM). It inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC50s=15.5 and 31.5µM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed. Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice. Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.
MDL:
MFCD00899035
Molecular Formula:
C30H37NO4
Molecular Weight:
475.62
Package Type:
Vial
PG:
III
Precautions:
P280
Product Description:
Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC50s=8.5 and 7.7nM, respectively), rabbit uterine PR (EC50=13.6nM), and rabbit thymic glucocorticoid receptor (GR; EC50=15.4nM). It is selective for human progesterone receptors over the human estrogen receptor (ER; EC50>10,000nM). It inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC50s=15.5 and 31.5µM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed. Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice. Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
O=C1CCC2=C3[C@@]([C@@](CC[C@]4(OC(C)=O)C(C)=O)([H])[C@]4(C)C[C@]3([H])C5=CC=C(N(C)C)C=C5)([H])CCC2=C1
Solubility Chemicals:
Soluble in DMSO (30mg/ml), ethanol (30mg/ml) or DMF (30mg/ml).
Source / Host:
Synthetic
Transportation:
Excepted Quantity
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) B.J. Attardi, et al.; J. Steroid Biochem. Mol. Biol. 88, 277 (2004) | (2) P.A. Orihuela; Curr. Opin. Investig. Drugs 8, 859 (2007) (Review) | (3) K. McKeage & J.D. Croxtall; Drugs 71, 935 (2011) (Review) | (4) B. Mozzanega, et al.; Trends Pharmacol. Sci. 34, 195 (2013) | (5) S. Nallasamy, et al.; Reprod. Sci. 20, 371 (2013) | (6) C.D. Gamarra-Luques, et al.; J. Ovarian Res. 7, 45 (2014) | (7) N. Esber, et al.; PLoS One 10, e0140795 (2015) | (8) L. Communcal, et al.; Oncotarget 7, 45317 (2016)